| Dr Stephen B Schaffer, MD | |
|
3841 Piper St, Suite T230, Anchorage, AK 99508-4624 | |
| (907) 279-8800 | |
| (907) 279-8810 |
| Full Name | Dr Stephen B Schaffer |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 21 Years |
| Location | 3841 Piper St, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720051089 | NPI | - | NPPES |
| 25527321 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 41238 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Alaska Medical Center | Anchorage, AK | Hospital |
| South Peninsula Hospital | Homer, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alaska Center For Ear Nose And Throat Inc | 7012901952 | 7 |
News Archive
While testosterone replacement therapies may be controversial in males, new research in The FASEB Journal may extend this controversy to females too. That's because research involving mice, appearing in the April 2015 issue, suggests that there is an association between low levels of androgens (which includes testosterone), and atherosclerosis and obesity in females.
The finding by researchers at Washington University School of Medicine in St. Louis shows that an enzyme known as cathepsin G regulates the ability of immune cells known as neutrophils to secrete chemicals that attract other immune cells and start the local inflammatory process. Over time, the excessive accumulation of immune cells can lead to tissue and cartilage damage in joints, causing pain and limiting mobility.
Protein Sciences Corporation, the manufacturer of Flublok, the new, pure influenza vaccine containing no egg proteins, influenza virus, preservatives (e.g., thimerosal), antibiotics, gelatin or latex, announced today that doses for the 2013-14 season have been released by the FDA and are now available.
TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee.
Growth in use among 20-somethings has doubled the use of the "morning-after" contraceptive pill in recent years, the Centers for Disease Control and Prevention says.
› Verified 1 days ago
| Entity Name | South Peninsula Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679566269 PECOS PAC ID: 5395636930 Enrollment ID: O20040323000583 |
News Archive
While testosterone replacement therapies may be controversial in males, new research in The FASEB Journal may extend this controversy to females too. That's because research involving mice, appearing in the April 2015 issue, suggests that there is an association between low levels of androgens (which includes testosterone), and atherosclerosis and obesity in females.
The finding by researchers at Washington University School of Medicine in St. Louis shows that an enzyme known as cathepsin G regulates the ability of immune cells known as neutrophils to secrete chemicals that attract other immune cells and start the local inflammatory process. Over time, the excessive accumulation of immune cells can lead to tissue and cartilage damage in joints, causing pain and limiting mobility.
Protein Sciences Corporation, the manufacturer of Flublok, the new, pure influenza vaccine containing no egg proteins, influenza virus, preservatives (e.g., thimerosal), antibiotics, gelatin or latex, announced today that doses for the 2013-14 season have been released by the FDA and are now available.
TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee.
Growth in use among 20-somethings has doubled the use of the "morning-after" contraceptive pill in recent years, the Centers for Disease Control and Prevention says.
› Verified 1 days ago
| Entity Name | Alaska Center For Ear Nose And Throat Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821046152 PECOS PAC ID: 7012901952 Enrollment ID: O20040413000836 |
News Archive
While testosterone replacement therapies may be controversial in males, new research in The FASEB Journal may extend this controversy to females too. That's because research involving mice, appearing in the April 2015 issue, suggests that there is an association between low levels of androgens (which includes testosterone), and atherosclerosis and obesity in females.
The finding by researchers at Washington University School of Medicine in St. Louis shows that an enzyme known as cathepsin G regulates the ability of immune cells known as neutrophils to secrete chemicals that attract other immune cells and start the local inflammatory process. Over time, the excessive accumulation of immune cells can lead to tissue and cartilage damage in joints, causing pain and limiting mobility.
Protein Sciences Corporation, the manufacturer of Flublok, the new, pure influenza vaccine containing no egg proteins, influenza virus, preservatives (e.g., thimerosal), antibiotics, gelatin or latex, announced today that doses for the 2013-14 season have been released by the FDA and are now available.
TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee.
Growth in use among 20-somethings has doubled the use of the "morning-after" contraceptive pill in recent years, the Centers for Disease Control and Prevention says.
› Verified 1 days ago
| Entity Name | Medical Network Of Alaska Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538414834 PECOS PAC ID: 3072618859 Enrollment ID: O20070424000329 |
News Archive
While testosterone replacement therapies may be controversial in males, new research in The FASEB Journal may extend this controversy to females too. That's because research involving mice, appearing in the April 2015 issue, suggests that there is an association between low levels of androgens (which includes testosterone), and atherosclerosis and obesity in females.
The finding by researchers at Washington University School of Medicine in St. Louis shows that an enzyme known as cathepsin G regulates the ability of immune cells known as neutrophils to secrete chemicals that attract other immune cells and start the local inflammatory process. Over time, the excessive accumulation of immune cells can lead to tissue and cartilage damage in joints, causing pain and limiting mobility.
Protein Sciences Corporation, the manufacturer of Flublok, the new, pure influenza vaccine containing no egg proteins, influenza virus, preservatives (e.g., thimerosal), antibiotics, gelatin or latex, announced today that doses for the 2013-14 season have been released by the FDA and are now available.
TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee.
Growth in use among 20-somethings has doubled the use of the "morning-after" contraceptive pill in recent years, the Centers for Disease Control and Prevention says.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephen B Schaffer, MD 3841 Piper St, Suite T230, Anchorage, AK 99508-4624 Ph: (907) 279-8800 | Dr Stephen B Schaffer, MD 3841 Piper St, Suite T230, Anchorage, AK 99508-4624 Ph: (907) 279-8800 |
News Archive
While testosterone replacement therapies may be controversial in males, new research in The FASEB Journal may extend this controversy to females too. That's because research involving mice, appearing in the April 2015 issue, suggests that there is an association between low levels of androgens (which includes testosterone), and atherosclerosis and obesity in females.
The finding by researchers at Washington University School of Medicine in St. Louis shows that an enzyme known as cathepsin G regulates the ability of immune cells known as neutrophils to secrete chemicals that attract other immune cells and start the local inflammatory process. Over time, the excessive accumulation of immune cells can lead to tissue and cartilage damage in joints, causing pain and limiting mobility.
Protein Sciences Corporation, the manufacturer of Flublok, the new, pure influenza vaccine containing no egg proteins, influenza virus, preservatives (e.g., thimerosal), antibiotics, gelatin or latex, announced today that doses for the 2013-14 season have been released by the FDA and are now available.
TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee.
Growth in use among 20-somethings has doubled the use of the "morning-after" contraceptive pill in recent years, the Centers for Disease Control and Prevention says.
› Verified 1 days ago
Dr. Jamie Swartz, DO Otolaryngology Medicare: Medicare Enrolled Practice Location: 673 Mdg/sghq, 5955 Zeamer Ave, Anchorage, AK 99506 Phone: 907-580-1035 | |
Christopher Edward Kowalski, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3841 Piper St., Suite T-230, Anchorage, AK 99508 Phone: 907-279-8800 Fax: 907-279-8810 | |
Dr. Mark B. Lorenz, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3730 Rhone Cir Ste 203, Anchorage, AK 99508 Phone: 907-563-3515 Fax: 907-563-3541 | |
Dr. Laura Louise Shively, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 4315 Diplomacy Dr, Anmc Otolaryngology Department, Anchorage, AK 99508 Phone: 907-729-1400 | |
Jack Arlyn Smith, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 4001 Dale St, #201, Anchorage, AK 99508 Phone: 907-561-1185 | |
Dr. James E Kallman, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 3841 Piper St, Suite T230, Anchorage, AK 99508 Phone: 907-279-8800 Fax: 907-279-8810 | |
Randall Leslie Plant, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 4315 Diplomacy Dr, Attn: Sherry Reedy, Anchorage, AK 99508 Phone: 907-729-3971 Fax: 907-729-1542 |